Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: A randomized, double-masked crossover study

Clinical Therapeutics

Volumn 30, Issue 7, 2008, Pages 1264-1271

  Torkildsen, Gail L ^a,b   Ousler III, George W ^b   Gomes, Paul ^b  

^a Andover Eye Associates   (United States)

^b ORA Clinical Research and Development   (United States)

Author keywords

azelastine; dry eye; epinastine; ketotifen; ocular protection index; seasonal allergic conjunctivitis

Indexed keywords

AZELASTINE; EPINASTINE; KETOTIFEN;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FLUORESCENCE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SKIN TEST; TASTE DISORDER; TEAR FILM;

ADULT; CONJUNCTIVITIS, ALLERGIC; CROSS-OVER STUDIES; DIBENZAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; IMIDAZOLES; KETOTIFEN; MALE; MAST CELLS; OPHTHALMIC SOLUTIONS; PHTHALAZINES; XEROPHTHALMIA;

EID: 48549104822     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(08)80050-1     Document Type: Article

References (38)

1. Wüthrich B., Brignoli R., Canevascini M., and Gerber M. Epidemiological survey in hay fever patients: Symptom prevalence and severity and influence on patient management. Schweiz Med Wochenschr 128 (1998) 139-143
2. Abelson M.B., Smith L., and Chapin M. Ocular allergic disease: Mechanisms, disease sub-types, treatment. Ocul Surf 1 (2003) 127-149
3. Epinastine 0.05% Clinical Pharmacology and Biopharmaceutical Review [Center for Drug Evaluation and Research Web site].
4. (June 17, 2008). http://www.fda.gov/cder/foi/nda/2003/21-565_Elestat_BioPharmr.pdf Accessed
5. Abelson M.B., and Pyun J. Histamine. In: Abelson M.B. (Ed). Allergic Diseases of the Eye (2000), WB Saunders, Philadelphia, Pa 57-68
6. Abelson M.B., Gomes P., Crampton H.J., et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 26 (2004) 35-47
7. Whitcup S.M., Bradford R., Lue J., et al. Efficacy and tolerability of ophthalmic epinastine: A randomized, doublemasked, parallel-group, active-and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther 26 (2004) 29-34
8. James I.G., Campbell L.M., Harrison J.M., et al. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhinoconjunctivitis. Curr Med Res Opin 19 (2003) 313-320
9. Greiner J.V., Mundorf T., Dubiner H., et al. Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis. Am J Ophthalmol 136 (2003) 1097-1105
10. Kidd M., McKenzie S.H., Steven I., et al., for the Australian Ketotifen Study Group. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br J Ophthalmol 87 (2003) 1206-1211
11. Tasaka K. Epinastine: An update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. Drugs Today (Barc) 36 (2000) 735-757
12. Leonardi A., and Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: A double-masked, environmental study of patient preference. Curr Med Res Opin 20 (2004) 1167-1173
13. Ousler III G.W., Workman D.A., and Torkildsen G.L. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 29 (2007) 611-616
14. Artal M.N., Luna J.D., and Discepola M. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. Acta Ophthalmol Scand Suppl 230 (2000) 64-65
15. Ousler G.W., Wilcox K.A., Gupta G., and Abelson M.B. An evaluation of the ocular drying effects of 2 systemic antihistamines: Loratadine and cetirizine hydrochloride. Ann Allergy Asthma Immunol 93 (2004) 460-464
16. Welch D., Ousler III G.W., Nally L.A., et al. Ocular drying associated with oral antihistamines (loratadine) in the normal population-an evaluation of exaggerated dose effect. Adv Exp Med Biol 506 (2002) 1051-1055
17. Abelson M.B., Doane M.G., and Ousler G. Tear film and blink dynamics. In: Albert D.M., and Miller J.W. (Eds). Principles and Practice of Ophthalmology. 3rd ed (2008), Saunders Elsevier, Philadelphia, Pa 281-292
18. Lemp M.A. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J 21 (1995) 221-232
19. Methodologies to diagnose and monitor dry eye disease: Report of the Diagnostic Methodology Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 5 (2007) 108-152
20. Ousler III G.W., Wilcox Hagberg K., Schindelar M., et al. The Ocular Protection Index. Cornea 27 (2008) 509-513
21. Granet D., Lichtenstein S.J., Onofrey B., and Katz J.A. An assessment of the tolerability of moxifloxacin 0.5% compared to azithromycin 1.0% in DuraSite. Clin Ophthal 1 (2007) 5195-5225
22. Greiner J.V., and Minno G. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model. Clin Ther 25 (2003) 1988-2005
23. Ousler III G.W., Anderson R.T., and Osborn K.E. The effect of senofilcon A contact lenses compared to habitual contact lenses on ocular discomfort during exposure to a controlled adverse environment. Curr Med Res Opin 24 (2008) 335-341
24. Abelson M.B., Ousler III G.W., Nally L.A., et al. Alternative reference values for tear film break up time in normal and dry eye populations. Adv Exp Med Biol 506 (2002) 1121-1125
25. Ousler G.W., Gomes P.J., Welch D., and Abelson M.B. Methodologies for the study of ocular surface disease. Ocul Surf 3 (2005) 143-154
26. In: Rosner B. (Ed). Fundamentals of Biostatistics (2006), Duxbury Press, Boston, Mass
27. Elestat label approved on 8/15/2005. NDA no. 21-565/S-005.
28. (July 3, 2008). http://www.fda.gov/cder/foi/label/2005/021565s005lbl.pdf Accessed
29. Optivar label approved 4/30/2004. NDA no. 021127.
30. (July 3, 2008). http://www.fda.gov/cder/foi/label/2004/21127Slr007,008_optivar_lbl.pdf Accessed
31. Zaditor label approved 10/19/2006. NDA no. 021066.
32. (July 3, 2008). http://www.fda.gov/cder/foi/label/2006/021066s011lbl.pdf Accessed
33. Zaditor label approved 7/20/2001. NDA no. 021066.
34. (July 3, 2008). http://www.fda.gov/cder/foi/label/2006/021066s4lbl.pdf Accessed
35. Lekhanont K., Park C.Y., Combs J.C., et al. Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye. J Ocul Pharmacol Ther 23 (2007) 83-88
36. Villareal A.L., Farley W., and Pflugfelder S.C. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens 32 (2006) 272-276
37. Krokhmal L., Gomes P., Welch D., and Abelson M.B. The incidence of dry eye with topical anti-allergic therapies. Invest Ophthalmol Vis Sci 48 (2007) E-2300
38. Leonardi A., and Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: A double-masked, environmental study of patient preference. Curr Med Res Opin 20 (2004) 1167-1173